Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.612
-0.018 (-2.90%)
At close: Apr 28, 2026, 4:00 PM EDT
0.612
0.00 (0.00%)
After-hours: Apr 28, 2026, 8:00 PM EDT
Oragenics Employees
Oragenics had 3 employees as of December 31, 2025. The number of employees decreased by 2 or -40.00% compared to the previous year.
Employees
3
Change (1Y)
-2
Growth (1Y)
-40.00%
Revenue / Employee
n/a
Profits / Employee
-$3,280,829
Market Cap
2.65M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Calidi Biotherapeutics | 29 |
| Virax Biolabs Group | 19 |
| GeoVax Labs | 17 |
| Silexion Therapeutics | 14 |
| Decoy Therapeutics | 11 |
| Adial Pharmaceuticals | 5 |
OGEN News
- 15 days ago - Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - GlobeNewsWire
- 4 weeks ago - Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - GlobeNewsWire
- 6 weeks ago - ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - GlobeNewsWire
- 6 weeks ago - ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - GlobeNewsWire
- 7 weeks ago - Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia - GlobeNewsWire
- 2 months ago - Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy - GlobeNewsWire
- 3 months ago - Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - GlobeNewsWire
- 5 months ago - Oragenics Q3 2025 Shareholder Update - Business Wire